Conference Coverage

Do Neurologists Adequately Screen Patients With MS for Cognitive Impairment and Depression?


 

Study May Have Limited Generalizability

The study results may not accurately reflect current practice throughout the country. “The small sample size and relatively low proportions of racial minorities may limit the ability to generalize these results and necessitate large-scale studies,” said Dr. Buckle and colleagues. “Future research should examine healthcare disparities in MS and underlying contributors (eg, bias and perceptions) that hinder the use of formal screening tools in MS patients.”

—Erik Greb

Suggested Reading

Benedict RH, Cox D, Thompson LL, et al. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler. 2004;10(6):675-658.

Parmenter BA, Weinstock-Guttman B, Garg N, et al. Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. Mult Scler. 2007;13(1):52-57.

Pages

Recommended Reading

MS: Past, Present, and Future
ICYMI Multiple Sclerosis
Rituximab May Provide Greater Benefits Than Other First-Line MS Therapies
ICYMI Multiple Sclerosis
MAGNIMS and McDonald Criteria Have Similar Accuracy
ICYMI Multiple Sclerosis
Trial of clozapine, risperidone halted in MS
ICYMI Multiple Sclerosis
‘Real-world evidence’ used to compare agents for relapsing-remitting MS
ICYMI Multiple Sclerosis
VIDEO: Advanced practice providers take on many roles in MS care
ICYMI Multiple Sclerosis
Adil Harroud, MD
ICYMI Multiple Sclerosis
VIDEO: Teriflunomide and dimethyl fumarate are comparable in relapsing-remitting MS
ICYMI Multiple Sclerosis
Physicians often bypass cognition, depression screening in MS
ICYMI Multiple Sclerosis
Study identifies characteristics that may constitute the MS prodrome
ICYMI Multiple Sclerosis

Related Articles